Previous 10 | Next 10 |
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro PR Newswire The Company's Emergency Use Authorization submission is for the new Co-Dx PCR Pro instrument and COVID-19 test kit, designed for point-of-care and at-home. The menu of tests in development for the...
Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023 PR Newswire SALT LAKE CITY , Nov. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a mo...
2023-11-09 19:59:09 ET Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Confe...
2023-11-09 16:14:11 ET More on Co-Diagnostics Co-Diagnostics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Co-Diagnostics Historical earnings data for Co-Diagnostics Financial information for Co-Diagnostics For further details see: ...
Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results PR Newswire Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform. SALT LAKE CITY , ...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Co-Diagnostics Inc. (CODX) is expected to report $-0.29 for Q3 2023
Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development PR Newswire Company to use funds awarded by the Bill & Melinda Gates Foundation toward the tuberculosis test for its Co-Dx™ PCR platform SALT LAKE CITY , ...
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023 PR Newswire SALT LAKE CITY , Oct. 31, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a...
Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developmen...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21 PR Newswire SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented plat...